MARKET

AMPH

AMPH

Amphastar Pharma
NASDAQ
39.78
-0.27
-0.67%
Closed 16:02 06/20 EDT
OPEN
40.01
PREV CLOSE
40.05
HIGH
40.71
LOW
39.70
VOLUME
249.26K
TURNOVER
0
52 WEEK HIGH
67.66
52 WEEK LOW
38.43
MARKET CAP
1.95B
P/E (TTM)
13.71
1D
5D
1M
3M
1Y
5Y
Those who invested in Amphastar Pharmaceuticals (NASDAQ:AMPH) three years ago are up 101%
Amphastar Pharmaceuticals, Inc. Share price has risen 101% in the last three years. The company has grown its earnings per share at 291% per year over three years, but the share price hasn't kept pace. Amphastar pharmaceuticals shareholders are down 26% for the year. Long term shareholders have made a gain of 15% a year over half a decade. The share price of the company has softened 2.8% over the last week.
Simply Wall St · 4d ago
Weekly Report: what happened at AMPH last week (0610-0614)?
Weekly Report · 4d ago
Weekly Report: what happened at AMPH last week (0603-0607)?
Weekly Report · 06/10 09:08
Amphastar Pharmaceuticals Advances Governance and Shareholder Value
TipRanks · 06/04 21:02
Amphastar adds $50M to share buyback program
Amphastar Pharmaceuticals adds $50M to share buyback program. Generic drug developer has lost more than 30% of its value this year. Amphastar says the move will counter the effect of share dilution created by employee compensation. The company's board of directors greenlighted the increase on Monday.
Seeking Alpha · 06/04 13:29
AMPHASTAR PHARMACEUTICALS INC: AUTHORIZED A $50 MLN INCREASE TO COMPANY'S SHARE BUYBACK PROGRAM
Reuters · 06/04 10:17
Weekly Report: what happened at AMPH last week (0527-0531)?
Weekly Report · 06/03 09:09
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has a low price-to-earnings ratio of 17x. The company's earnings growth is in positive territory compared to the rest of the U.S. Market. Its forecast growth is higher than the wider market, but the company's P/E may be low because investors think its earnings will fall away soon. Amphastar has posted a 67% increase in earnings in the last year.
Simply Wall St · 05/30 11:34
More
About AMPH
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.

Webull offers Amphastar Pharmaceuticals Inc stock information, including NASDAQ: AMPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMPH stock methods without spending real money on the virtual paper trading platform.